1. PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-α/VEGF pathway in endometrial cancer
   Aki Miyasaka et al, 2015, Gynecologic Oncology CrossRef
2. Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas
   Kanako Inaba et al, 2015, Gynecologic Oncology CrossRef
3. Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies
   Katsutoshi Oda et al, 2016, Journal of Obstetrics and Gynaecology Research CrossRef
4. Aberrant Cyclin D1 splicing in cancer: from molecular mechanism to therapeutic modulation
   Jing Wang et al, 2023, Cell Death & Disease CrossRef
5. Oncogenic c-terminal cyclin D1 (CCND1) mutations are enriched in endometrioid endometrial adenocarcinomas
   Jia Xu et al, 2018, PLOS ONE CrossRef
6. CCND1-Induced Autophagy Contributes to Lymph Node Metastasis in Endometrial Cancer
   Yi Su et al, 2023, Hormone and Metabolic Research CrossRef
7. Characterization of cytoplasmic cyclin D1 as a marker of invasiveness in cancer
   Noel P. Fusté et al, 2016, Oncotarget CrossRef
8. Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy
   Yuji Ikeda et al, 2015, British Journal of Cancer CrossRef
9. Role of microRNA-4458 in patients with non-small-cell lung cancer
   Lidao Bao et al, 2016, Oncology Letters CrossRef
10. Calcineurin regulates cyclin D1 stability through dephosphorylation at T286
    Takahiro Goshima et al, 2019, Scientific Reports CrossRef
11. Degrons in cancer
    Bálint Mészáros et al, 2017, Science Signaling CrossRef
12. Single-cell analysis of gastric pre-cancerous and cancer lesions reveals cell lineage diversity and intratumoral heterogeneity
    Jihyun Kim et al, 2022, npj Precision Oncology CrossRef